首程控股(00697.HK)建議採納股權激勵計劃
格隆匯10月12日丨首程控股(00697.HK)發佈公吿,根據相關要求,公司已收到北京市國資委對股權激勵計劃的批准,董事會已作出決議,提議由股東在股東大會上批准該計劃的採納。該計劃不構成上市規則第17章規定的股份期權計劃,而是該公司的一項酌情計劃。
該計劃的目的是為了公司的長遠發展,使僱員、公司和股東的利益保持一致,吸引、激勵和留住人才,建立和完善公司的長期激勵機制,以實現進一步提升股東價值的目標。在該計劃項下授予的獎勵行權時可授予的股份總數不得超過173,139,000股,約佔截至該公吿日期已發行股份總數的2.37%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.